Prophylactic use of NovoSeven in surgical procedures in a patient with coagulation disorders in the course of abdominal actinomycosis
More details
Hide details
Department of Anesthesiology and Intensive Care, Faculty of Medical Sciences, University of Warmia and Mazury in Olsztyn, Poland
Department of Anesthesiology and Intensive Care, Provincial Specialist Hospital in Olsztyn, Poland
Emergency Department, Provincial Specialist Hospital in Olsztyn, Poland
Dariusz Onichimowski   

Department of Anesthesiology and Intensive Care, Provincial Specialist Hospital in Olsztyn, Żołnierska 18, 10-561 Olsztyn, Poland. Tel.: +48 89 538 86 25; fax: +48 89 533 78 82.
Submission date: 2011-07-11
Acceptance date: 2011-11-30
Publication date: 2020-04-10
Pol. Ann. Med. 2012;19(1):63–66
Recombinant activated factor VII (rVIIa – NovoSeven, Novo Nordisk Pharm, Denmark) is commonly used in the treatment of coagulation disorders. At present, numerous studies are being carried out with reference to expanding the indications for this drug, especially in preventing perioperative bleedings in patients at a high risk for bleeding as a result of various coagulation disorders such as hemophilia.

The aim of this work was to assess the effectiveness of a prophylactic use of rVIIa in patients with complex coagulation disorders before surgery or invasive procedures.

Material and methods:
This paper presents a case report concerning a patient with abdominal actinomycosis hospitalized at the Intensive Care Unit (ICU), who developed peritonitis and severe coagulopathy of a complex etiology and required massive transfusions of blood products. During his 200-day hospitalization, initial treatment comprised invasive procedures without the preventive use of rVIIa; however, later on due to severe bleedings accompanying treatments, NovoSeven was administered as a preoperative prophylaxis. After treatment, blood loss related to invasive procedures and transfusion requirements were assessed and compared to no drug use during the invasive procedures as well as during prophylactic NovoSeven administration.

Results and discussion:
Preoperative use of NovoSeven resulted in reducing significant perioperative bleedings; moreover, there was a decrease in the requirement for postoperative blood transfusions.

Supplementation of morphotic blood elements and coagulation factors in the form of fresh frozen plasma and cryoprecipitate frequently does not result in obtaining the desired outcome of clinically effective hemostasis. The additional supply of rVIIa in such cases enables one to control bleeding. Preventive use of NovoSeven seems to be effective in reducing the frequency of perioperative bleedings that require blood products transfusions, particularly in patients with complex coagulopathy.

None declared.
Agarwal N, Spahr JE, Rodgers GM. Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa. Blood Coagul Fibrinolysis. 2007;18(2):205–207.
Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, et al. The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. Transfusion. 2009;49(suppl 5):240–247.
Franchini M, Manzato F, Salvagno GL, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007;18(7):589–593.
Giżewski T, Kowalski IM, Zarzycki D, Radomska-Wilczewska A, Lewandowski R, Kotwicki T. Model of self-learning system in medical diagnostics. Pol Ann Med. 2008;15(1):34–42.
Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol. 2007;41(suppl 1):25–29.
Heslet L, Nielsen JD, Levi M, Sengeløv H, Johansson PI. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Crit Care. 2006;10(6):177.
Johansson PI, Eriksen K, Nielsen SL, Rojkjaer R, Alsbjørn B. Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting – results of a single centre pilot study. Burns. 2007;33(4):435–440.
Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology. 2004;9(5–6):317–332.
MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion. 2005;45(9):1434–1442.
Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, et al. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang. 2004;87(1):34–40.
Sachs B, Delacy D, Green J, Graham RS, Ramsay J, Kreisler N, et al. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. Spine. 2007;32(21):2285–2293.
Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg. 2006;191(2):245–249.